Does the media favor PHAR or NAMS?

In the previous week, NewAmsterdam Pharma had 6 more articles in the media than Pharming Group. MarketBeat recorded 11 mentions for NewAmsterdam Pharma and 5 mentions for Pharming Group. NewAmsterdam Pharma's average media sentiment score of 1.18 beat Pharming Group's score of 0.54 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 5 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ADPT or PHAR?

In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Pharming Group. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 5 mentions for Pharming Group. Adaptive Biotechnologies' average media sentiment score of 0.85 beat Pharming Group's score of 0.54 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 4 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, PHAR or OGN?

Organon & Co. has higher revenue and earnings than Pharming Group. Organon & Co. is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Pharming Group $369.49M 2.41 $2.85M $0.16 78.78 Organon & Co. $6.16B 0.58 $187M $0.93 14.54

Does the media prefer PHAR or OGN?

In the previous week, Pharming Group had 2 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Pharming Group and 3 mentions for Organon & Co.. Pharming Group's average media sentiment score of 0.54 beat Organon & Co.'s score of 0.48 indicating that Pharming Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor ARQT or PHAR?

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Pharming Group. MarketBeat recorded 6 mentions for Arcutis Biotherapeutics and 5 mentions for Pharming Group. Arcutis Biotherapeutics' average media sentiment score of 0.99 beat Pharming Group's score of 0.54 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to GPCR or PHAR?

In the previous week, Structure Therapeutics had 4 more articles in the media than Pharming Group. MarketBeat recorded 9 mentions for Structure Therapeutics and 5 mentions for Pharming Group. Structure Therapeutics' average media sentiment score of 1.09 beat Pharming Group's score of 0.54 indicating that Structure Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Pharming Group 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Pharming Group (PHAR) Competitors

$12.60 -0.57 (-4.29%)

Closing price 07/24/2026 03:59 PM Eastern

Extended Trading

$12.60 0.00 (0.00%)

As of 07/24/2026 07:34 PM Eastern

Compare

PHAR vs. NAMS, ADPT, OGN, ARQT, and GPCR

Should you buy Pharming Group stock or one of its competitors? MarketBeat compares Pharming Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Pharming Group include NewAmsterdam Pharma (NAMS), Adaptive Biotechnologies (ADPT), Organon & Co. (OGN), Arcutis Biotherapeutics (ARQT), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Pharming Group compare to NewAmsterdam Pharma?

Pharming Group (NASDAQ:PHAR) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, risk, institutional ownership, analyst recommendations, earnings, profitability, media sentiment and dividends.

Pharming Group has a net margin of 3.30% compared to NewAmsterdam Pharma's net margin of -943.23%. Pharming Group's return on equity of 4.64% beat NewAmsterdam Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

0.0% of Pharming Group shares are owned by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are owned by institutional investors. 2.1% of Pharming Group shares are owned by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Pharming Group currently has a consensus target price of $38.33, suggesting a potential upside of 204.11%. NewAmsterdam Pharma has a consensus target price of $49.42, suggesting a potential upside of 66.72%. Given Pharming Group's higher probable upside, research analysts plainly believe Pharming Group is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.93

In the previous week, NewAmsterdam Pharma had 6 more articles in the media than Pharming Group. MarketBeat recorded 11 mentions for NewAmsterdam Pharma and 5 mentions for Pharming Group. NewAmsterdam Pharma's average media sentiment score of 1.18 beat Pharming Group's score of 0.54 indicating that NewAmsterdam Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pharming Group has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$369.49M	2.41	$2.85M	$0.16	78.78
NewAmsterdam Pharma	$22.57M	153.56	-$203.82M	-$1.79	N/A

Pharming Group has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.08, indicating that its stock price is 92% less volatile than the broader market.

Summary

NewAmsterdam Pharma beats Pharming Group on 9 of the 17 factors compared between the two stocks.

How does Pharming Group compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

Pharming Group has higher revenue and earnings than Adaptive Biotechnologies. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$276.98M	12.87	-$59.50M	-$0.33	N/A
Pharming Group	$369.49M	2.41	$2.85M	$0.16	78.78

Pharming Group has a net margin of 3.30% compared to Adaptive Biotechnologies' net margin of -16.82%. Pharming Group's return on equity of 4.64% beat Adaptive Biotechnologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-16.82%	-40.06%	-16.64%
Pharming Group	3.30%	4.64%	2.55%

Adaptive Biotechnologies has a beta of 2.07, meaning that its stock price is 107% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market.

Adaptive Biotechnologies currently has a consensus price target of $20.83, indicating a potential downside of 6.45%. Pharming Group has a consensus price target of $38.33, indicating a potential upside of 204.11%. Given Pharming Group's higher possible upside, analysts clearly believe Pharming Group is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

99.2% of Adaptive Biotechnologies shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 5.7% of Adaptive Biotechnologies shares are owned by company insiders. Comparatively, 2.1% of Pharming Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Pharming Group. MarketBeat recorded 8 mentions for Adaptive Biotechnologies and 5 mentions for Pharming Group. Adaptive Biotechnologies' average media sentiment score of 0.85 beat Pharming Group's score of 0.54 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Adaptive Biotechnologies and Pharming Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Organon & Co.?

Pharming Group (NASDAQ:PHAR) and Organon & Co. (NYSE:OGN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

Organon & Co. has a net margin of 3.99% compared to Pharming Group's net margin of 3.30%. Organon & Co.'s return on equity of 99.95% beat Pharming Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pharming Group	3.30%	4.64%	2.55%
Organon & Co.	3.99%	99.95%	6.22%

Organon & Co. has higher revenue and earnings than Pharming Group. Organon & Co. is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pharming Group	$369.49M	2.41	$2.85M	$0.16	78.78
Organon & Co.	$6.16B	0.58	$187M	$0.93	14.54

Pharming Group currently has a consensus target price of $38.33, indicating a potential upside of 204.11%. Organon & Co. has a consensus target price of $11.40, indicating a potential downside of 15.71%. Given Pharming Group's stronger consensus rating and higher possible upside, analysts clearly believe Pharming Group is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 77.4% of Organon & Co. shares are held by institutional investors. 2.1% of Pharming Group shares are held by insiders. Comparatively, 1.6% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Pharming Group had 2 more articles in the media than Organon & Co.. MarketBeat recorded 5 mentions for Pharming Group and 3 mentions for Organon & Co.. Pharming Group's average media sentiment score of 0.54 beat Organon & Co.'s score of 0.48 indicating that Pharming Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Pharming Group has a beta of -0.04, suggesting that its stock price is 104% less volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.54, suggesting that its stock price is 54% more volatile than the broader market.

Summary

Pharming Group and Organon & Co. tied by winning 8 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability.

In the previous week, Arcutis Biotherapeutics had 1 more articles in the media than Pharming Group. MarketBeat recorded 6 mentions for Arcutis Biotherapeutics and 5 mentions for Pharming Group. Arcutis Biotherapeutics' average media sentiment score of 0.99 beat Pharming Group's score of 0.54 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arcutis Biotherapeutics presently has a consensus target price of $34.00, suggesting a potential upside of 24.31%. Pharming Group has a consensus target price of $38.33, suggesting a potential upside of 204.11%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Pharming Group has lower revenue, but higher earnings than Arcutis Biotherapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$415.62M	8.23	-$16.14M	-$0.03	N/A
Pharming Group	$369.49M	2.41	$2.85M	$0.16	78.78

Pharming Group has a net margin of 3.30% compared to Arcutis Biotherapeutics' net margin of -0.57%. Pharming Group's return on equity of 4.64% beat Arcutis Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%
Pharming Group	3.30%	4.64%	2.55%

Arcutis Biotherapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its stock price is 104% less volatile than the broader market.

0.0% of Pharming Group shares are held by institutional investors. 9.4% of Arcutis Biotherapeutics shares are held by insiders. Comparatively, 2.1% of Pharming Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Arcutis Biotherapeutics and Pharming Group tied by winning 8 of the 16 factors compared between the two stocks.

How does Pharming Group compare to Structure Therapeutics?

Structure Therapeutics (NASDAQ:GPCR) and Pharming Group (NASDAQ:PHAR) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, media sentiment, analyst recommendations and dividends.

Pharming Group has higher revenue and earnings than Structure Therapeutics. Structure Therapeutics is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A
Pharming Group	$369.49M	2.41	$2.85M	$0.16	78.78

Pharming Group has a net margin of 3.30% compared to Structure Therapeutics' net margin of 0.00%. Pharming Group's return on equity of 4.64% beat Structure Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-24.91%	-23.67%
Pharming Group	3.30%	4.64%	2.55%

Structure Therapeutics has a beta of -1.5, indicating that its share price is 250% less volatile than the broader market. Comparatively, Pharming Group has a beta of -0.04, indicating that its share price is 104% less volatile than the broader market.

91.8% of Structure Therapeutics shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 5.5% of Structure Therapeutics shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Structure Therapeutics currently has a consensus price target of $110.55, indicating a potential upside of 125.05%. Pharming Group has a consensus price target of $38.33, indicating a potential upside of 204.11%. Given Pharming Group's higher possible upside, analysts plainly believe Pharming Group is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89
Pharming Group	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

In the previous week, Structure Therapeutics had 4 more articles in the media than Pharming Group. MarketBeat recorded 9 mentions for Structure Therapeutics and 5 mentions for Pharming Group. Structure Therapeutics' average media sentiment score of 1.09 beat Pharming Group's score of 0.54 indicating that Structure Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Structure Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Pharming Group	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Pharming Group beats Structure Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Pharming Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PHAR vs. The Competition

Export

Metric	Pharming Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$892.86M	$3.67B	$6.86B	$12.25B
Dividend Yield	N/A	2.19%	2.67%	9.79%
P/E Ratio	78.79	21.48	27.14	23.64
Price / Sales	2.41	169.92	517.01	89.03
Price / Cash	65.67	157.90	50.54	59.64
Price / Book	3.19	7.88	10.28	6.07
Net Income	$2.85M	$23.86M	$3.60B	$331.99M
7 Day Performance	-6.42%	-3.82%	-1.27%	-0.63%
1 Month Performance	-5.01%	-2.61%	-0.37%	-2.00%
1 Year Performance	22.86%	32.79%	18.30%	13.62%

Pharming Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PHAR Pharming Group	2.5297 of 5 stars	$12.61 -4.3%	$38.33 +204.1%	+25.4%	$892.86M	$369.49M	78.79	280	Upcoming Earnings Short Interest Increase Gap Down
NAMS NewAmsterdam Pharma	2.9051 of 5 stars	$30.88 +4.1%	$49.42 +60.1%	+26.7%	$3.61B	$22.50M	N/A	4	News Coverage
ADPT Adaptive Biotechnologies	1.5031 of 5 stars	$22.16 +1.4%	$20.83 -6.0%	+108.9%	$3.55B	$276.98M	N/A	790
OGN Organon & Co.	2.2134 of 5 stars	$13.53 +0.3%	$11.40 -15.7%	+34.4%	$3.55B	$6.22B	14.54	10,000	News Coverage
ARQT Arcutis Biotherapeutics	3.4119 of 5 stars	$27.95 +1.5%	$34.00 +21.6%	+82.1%	$3.50B	$376.07M	N/A	150	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PHAR) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Pharming Group (PHAR) Competitors

PHAR vs. NAMS, ADPT, OGN, ARQT, and GPCR

How does Pharming Group compare to NewAmsterdam Pharma?

Summary

How does Pharming Group compare to Adaptive Biotechnologies?

Summary

How does Pharming Group compare to Organon & Co.?

Summary

How does Pharming Group compare to Arcutis Biotherapeutics?

Summary

How does Pharming Group compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Pharming Group (PHAR) Competitors

PHAR vs. NAMS, ADPT, OGN, ARQT, and GPCR

How does Pharming Group compare to NewAmsterdam Pharma?

Is PHAR or NAMS more profitable?

Do insiders & institutionals believe in PHAR or NAMS?

Do analysts recommend PHAR or NAMS?

Does the media favor PHAR or NAMS?

Which has higher earnings & valuation, PHAR or NAMS?

Which has more risk and volatility, PHAR or NAMS?

Summary

How does Pharming Group compare to Adaptive Biotechnologies?

Which has better earnings & valuation, ADPT or PHAR?

Is ADPT or PHAR more profitable?

Which has more volatility & risk, ADPT or PHAR?

Do analysts prefer ADPT or PHAR?

Do insiders & institutionals have more ownership in ADPT or PHAR?

Does the media refer more to ADPT or PHAR?

Summary

How does Pharming Group compare to Organon & Co.?

Is PHAR or OGN more profitable?

Which has better valuation & earnings, PHAR or OGN?

Do analysts prefer PHAR or OGN?

Do insiders and institutionals have more ownership in PHAR or OGN?

Does the media prefer PHAR or OGN?

Which has more risk and volatility, PHAR or OGN?

Summary

How does Pharming Group compare to Arcutis Biotherapeutics?

Does the media favor ARQT or PHAR?

Do analysts rate ARQT or PHAR?

Which has preferable valuation and earnings, ARQT or PHAR?

Is ARQT or PHAR more profitable?

Which has more risk and volatility, ARQT or PHAR?

Do insiders & institutionals believe in ARQT or PHAR?

Summary

How does Pharming Group compare to Structure Therapeutics?

Which has better earnings and valuation, GPCR or PHAR?

Is GPCR or PHAR more profitable?

Which has more risk & volatility, GPCR or PHAR?

Do institutionals & insiders have more ownership in GPCR or PHAR?

Do analysts recommend GPCR or PHAR?

Does the media refer more to GPCR or PHAR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PHAR vs. The Competition

Pharming Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools